- Stocks
- Pharma & Healthcare
- Aarti Drugs
Aarti Drugs share price
NSE: AARTIDRUGSPharma & HealthcareDrug Manufacturers - Specialty & Generic
Aarti Drugs at a glance
Aarti Drugs (NSE: AARTIDRUGS) closed at ₹381.15 on 22 Oct 2026, down 1.51% on the day. With a market capitalisation of ₹3,479 Cr, it ranks 919th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 17.9× trailing earnings, against a return on equity of 12.6% in FY26. Over the past year the share price has fallen 24.5%. Its 52-week range is ₹318.95 (30 Mar 2026) to ₹534.00 (10 Nov 2025); the last close is 28.6% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹703 Cr (+19.0% year on year) and net profit ₹50 Cr (−7.1%), on a consolidated basis. Promoters held 54.43% of the company as of 30 Jun 2026; 2.50% of promoter shares were pledged.
Key numbers
- Market cap
- ₹3,479 CrRank 919 on NSE
- P/E (trailing)
- 17.9×
- Price to book
- 1.88×FY26
- EPS (TTM)
- ₹20.93to Q1 FY27
- ROE
- 12.6%FY26
- ROCE
- 12.9%FY26
- Debt to equity
- 0.37FY26
- Net profit margin
- 7.6%FY26
- Book value / share
- ₹169.70FY26
- 52-week high
- ₹534.0010 Nov 2025
- 52-week low
- ₹318.9530 Mar 2026
- 1-year return
- −24.5%
- RSI (14-day)
- 29.8
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −1.51% | −5.4% | −12.6% | −7.3% | −24.5% |
Aarti Drugs quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹598 Cr | ₹557 Cr | ₹677 Cr | ₹591 Cr | ₹653 Cr | ₹602 Cr | ₹720 Cr | ₹703 Cr |
| Revenue YoY | −6.7% | −8.1% | +9.2% | +6.3% | +9.1% | +8.1% | +6.4% | +19.0% |
| Net profit | ₹35 Cr | ₹37 Cr | ₹63 Cr | ₹54 Cr | ₹45 Cr | ₹41 Cr | ₹55 Cr | ₹50 Cr |
| Net profit YoY | −11.7% | +1.0% | +32.7% | +62.2% | +29.2% | +9.3% | −12.0% | −7.1% |
| Net margin | 5.8% | 6.7% | 9.3% | 9.1% | 6.9% | 6.7% | 7.7% | 7.1% |
| EPS | ₹3.83 | ₹4.06 | ₹6.88 | ₹5.91 | ₹4.95 | ₹4.44 | ₹6.05 | ₹5.49 |
Aarti Drugs financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹2,155 Cr | ₹2,489 Cr | ₹2,716 Cr | ₹2,529 Cr | ₹2,387 Cr | — |
| Operating profit | ₹369 Cr | ₹270 Cr | ₹224 Cr | ₹236 Cr | ₹212 Cr | — |
| Net profit | ₹280 Cr | ₹205 Cr | ₹166 Cr | ₹172 Cr | ₹168 Cr | — |
| EPS (₹) | ₹30.00 | ₹22.00 | ₹18.00 | ₹19.00 | ₹18.00 | — |
| Cash from operations | ₹155 Cr | ₹70 Cr | ₹134 Cr | ₹359 Cr | ₹245 Cr | — |
| Total debt | ₹148 Cr | ₹139 Cr | ₹205 Cr | ₹275 Cr | ₹284 Cr | ₹257 Cr |
| Shareholders' equity | ₹913 Cr | ₹1,036 Cr | ₹1,192 Cr | ₹1,282 Cr | ₹1,369 Cr | ₹1,549 Cr |
Aarti Drugs shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 55.48% | 55.22% | 54.72% | 55.03% | 55.03% | 54.43% |
| Foreign institutions | 2.25% | 2.26% | 2.69% | 2.15% | 1.58% | 1.52% |
| Domestic institutions | 9.70% | 9.94% | 9.90% | 10.12% | 10.22% | 10.29% |
| Non-institutions | 32.57% | 32.58% | 32.69% | 32.70% | 33.18% | 33.75% |
| Promoter shares pledged | — | — | — | — | 2.47% | 2.50% |
Aarti Drugs vs peers
The listed Pharma & Healthcare companies nearest to Aarti Drugs by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| GUFICBIOGufic Biosciences | ₹401.55 | +3.43% | +9.9% | ₹4,027 Cr | 62.7 | — |
| GUJTHEMGujarat Themis Biosyn | ₹365.70 | +4.88% | −11.9% | ₹3,985 Cr | 85.4 | — |
| UNICHEMLABUnichem Laboratories | ₹495.95 | −3.51% | +5.5% | ₹3,492 Cr | 13.8 | — |
| AARTIDRUGSAarti Drugs | ₹381.15 | −1.51% | −24.5% | ₹3,479 Cr | 17.9 | — |
| SOLARASolara Active Pharma Sciences | ₹650.75 | +1.48% | +11.8% | ₹3,140 Cr | — | — |
| INDSWFTLABInd-Swift Laboratories | ₹347.05 | +1.92% | +240.9% | ₹3,018 Cr | 71.6 | — |
| ADVENZYMESAdvanced Enzyme Technologies | ₹265.45 | +1.39% | −13.2% | ₹2,972 Cr | 17.6 | — |
Ask anything about Aarti Drugs
Pivot answers on the live chart with evidence you can check, and tests strategies against AARTIDRUGS's own history. Try: “Why has AARTIDRUGS moved over the last three months?” · “Backtest a 50-day moving-average crossover on AARTIDRUGS over five years” · “Compare AARTIDRUGS with GUFICBIO on margins and valuation”
Frequently asked questions about Aarti Drugs
What is the share price of Aarti Drugs today?
Aarti Drugs (NSE: AARTIDRUGS) last closed at ₹381.15 on 22 Oct 2026. Its 52-week high is ₹534.00 and its 52-week low is ₹318.95.
What is the market cap of Aarti Drugs?
Aarti Drugs' market capitalisation is ₹3,479 Cr (₹3,479 Cr) at the 22 Oct 2026 close, ranking 919th among the NSE companies Pivot tracks.
What is the P/E ratio of Aarti Drugs?
Aarti Drugs trades at a trailing P/E of 17.9. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 62.7.
What is the ROE and ROCE of Aarti Drugs?
Return on equity was 12.6% in FY26 and return on capital employed was 12.9% in FY26 (consolidated figures).
Is Aarti Drugs a debt-free company?
No. Aarti Drugs' debt-to-equity ratio was 0.37 in FY26, with total debt of ₹257 Cr.
What were Aarti Drugs' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Aarti Drugs reported revenue of ₹703 Cr, +19.0% year on year, and net profit of ₹50 Cr, −7.1% year on year.
How has Aarti Drugs stock performed over the last year?
Aarti Drugs' share price has fallen 24.5% over the past year, −7.3% over three months and −12.6% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Aarti Drugs?
As of 30 Jun 2026: promoters 54.43%, foreign institutions 1.52%, domestic institutions 10.29%, non-institutions 33.75%. 2.50% of promoter shares were pledged.
Who are Aarti Drugs' competitors?
The listed Pharma & Healthcare companies closest to Aarti Drugs by market cap are Gufic Biosciences, Gujarat Themis Biosyn, Unichem Laboratories, Solara Active Pharma Sciences, Ind-Swift Laboratories and Advanced Enzyme Technologies.
Is Aarti Drugs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Aarti Drugs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AARTIDRUGS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text